Shares of Repros Therapeutics Inc (NASDAQ:RPRX) dropped 1.4% during trading on Wednesday . The company traded as low as $2.03 and last traded at $2.08, with a volume of 93,398 shares traded. The stock had previously closed at $2.11.

Separately, Zacks Investment Research downgraded Repros Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Repros Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $2.25.

The stock’s market capitalization is $49.37 million. The company has a 50 day moving average price of $1.94 and a 200 day moving average price of $1.66.

Repros Therapeutics (NASDAQ:RPRX) last released its earnings results on Tuesday, August 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.02. Analysts expect that Repros Therapeutics Inc will post ($0.70) earnings per share for the current fiscal year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.